Original paper

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Volume: 40, Issue: 4_suppl, Pages: 378 - 378
Published: Jan 19, 2022
Paper Details
Title
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
Published Date
Jan 19, 2022
Volume
40
Issue
4_suppl
Pages
378 - 378
© 2025 Pluto Labs All rights reserved.